Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cindy H Chau

Showing results (51-60 of 78) with videos related to

Pageof 8
Sort By:
Biomolecules|June 27, 2024
Preclinical Evaluation of a Novel Series of Polyfluorinated Thalidomide Analogs in Drug-Resistant Multiple MyelomaBlaire E Barton, Matthew K Collins, Cindy H Chau, et al.
Biochemical and Biophysical Research Communications|August 3, 2025
Monoterpenoid fluorophthalimide IMiDs that lack human cereblon binding: synthesis and anti-proliferative, anti-angiogenic and anti-inflammatory activitiesWeiming Luo, Kathleen M Garchitorena, David Tweedie, et al.
Molecules (Basel, Switzerland)|December 5, 2020
Antiangiogenic Activity and in Silico Cereblon Binding Analysis of Novel Thalidomide AnalogsMegan L Peach, Shaunna L Beedie, Cindy H Chau, et al.
Molecular Cancer|April 30, 2014
Epidithiodiketopiperazines (ETPs) exhibit in vitro antiangiogenic and in vivo antitumor activity by disrupting the HIF-1α/p300 complex in a preclinical model of prostate cancerKelie M Reece, Emily D Richardson, Kristina M Cook, et al.
Clinical Genitourinary Cancer|April 25, 2020
Phase 2 Study of Seviteronel (INO-464) in Patients With Metastatic Castration-Resistant Prostate Cancer After Enzalutamide TreatmentRavi A Madan, Keith T Schmidt, Fatima Karzai, et al.
Journal of Cancer|January 12, 2024
Detection of Extracellular Vesicle-Derived RNA as Potential Prostate Cancer Biomarkers: Role of Cancer-type SLCO1B3 and ABCC3Kristi Y Lee, Erica L Beatson, Martina A Knechel, et al.
Marine Drugs|July 22, 2018
Preclinical Evaluation of Discorhabdins in Antiangiogenic and Antitumor ModelsEmily M Harris, Jonathan D Strope, Shaunna L Beedie, et al.
Medrxiv : the Preprint Server for Health Sciences|January 16, 2026
Molecular decoupling of lineage identity and morphology in aggressive variant prostate cancerChennan Li, JuanJuan Yin, Melissa L Abel, et al.
NPJ Precision Oncology|April 9, 2026
Integrative molecular analyses of lineage identity and morphology in aggressive variant prostate cancerChennan Li, JuanJuan Yin, Melissa L Abel, et al.
The Oncologist|May 31, 2022
A Single-arm Phase II Study Combining NLG207, a Nanoparticle Camptothecin, with Enzalutamide in Advanced Metastatic Castration-resistant Prostate Cancer Post-EnzalutamideKeith T Schmidt, Fatima Karzai, Marijo Bilusic, et al.
Pageof 8

Showing results (51-60 of 78) with videos related to

Sort By:
Pageof 8
Biomolecules|June 27, 2024
Preclinical Evaluation of a Novel Series of Polyfluorinated Thalidomide Analogs in Drug-Resistant Multiple MyelomaBlaire E Barton, Matthew K Collins, Cindy H Chau, et al.
Biochemical and Biophysical Research Communications|August 3, 2025
Monoterpenoid fluorophthalimide IMiDs that lack human cereblon binding: synthesis and anti-proliferative, anti-angiogenic and anti-inflammatory activitiesWeiming Luo, Kathleen M Garchitorena, David Tweedie, et al.
Molecules (Basel, Switzerland)|December 5, 2020
Antiangiogenic Activity and in Silico Cereblon Binding Analysis of Novel Thalidomide AnalogsMegan L Peach, Shaunna L Beedie, Cindy H Chau, et al.
Molecular Cancer|April 30, 2014
Epidithiodiketopiperazines (ETPs) exhibit in vitro antiangiogenic and in vivo antitumor activity by disrupting the HIF-1α/p300 complex in a preclinical model of prostate cancerKelie M Reece, Emily D Richardson, Kristina M Cook, et al.
Clinical Genitourinary Cancer|April 25, 2020
Phase 2 Study of Seviteronel (INO-464) in Patients With Metastatic Castration-Resistant Prostate Cancer After Enzalutamide TreatmentRavi A Madan, Keith T Schmidt, Fatima Karzai, et al.
Journal of Cancer|January 12, 2024
Detection of Extracellular Vesicle-Derived RNA as Potential Prostate Cancer Biomarkers: Role of Cancer-type SLCO1B3 and ABCC3Kristi Y Lee, Erica L Beatson, Martina A Knechel, et al.
Marine Drugs|July 22, 2018
Preclinical Evaluation of Discorhabdins in Antiangiogenic and Antitumor ModelsEmily M Harris, Jonathan D Strope, Shaunna L Beedie, et al.
Medrxiv : the Preprint Server for Health Sciences|January 16, 2026
Molecular decoupling of lineage identity and morphology in aggressive variant prostate cancerChennan Li, JuanJuan Yin, Melissa L Abel, et al.
NPJ Precision Oncology|April 9, 2026
Integrative molecular analyses of lineage identity and morphology in aggressive variant prostate cancerChennan Li, JuanJuan Yin, Melissa L Abel, et al.
The Oncologist|May 31, 2022
A Single-arm Phase II Study Combining NLG207, a Nanoparticle Camptothecin, with Enzalutamide in Advanced Metastatic Castration-resistant Prostate Cancer Post-EnzalutamideKeith T Schmidt, Fatima Karzai, Marijo Bilusic, et al.
Pageof 8